Systemic therapies for cutaneous T-cell lymphoma (CTCL).
| Treatment . | Response Duration, months (median) . |
|---|---|
| Abbreviations: TSEB, total skin electron beam; CAPO, cyclophosphamide, adriamycin, etoposide, vincristine, prednisone; VICOP-B, idarubicin, etoposide, cyclophosphamide, vincristine, bleomycin, prednisone; EPOCH, etoposide, vincristine, doxorubicin, bolus cyclophosphamide, oral prednisone; IFN, interferon; ONTAK, denileukin diftitox | |
| Pegylated liposomal doxorubicin (PEG-DOXO)10 | 15 |
| TSEB + CAPO31 | 13.7 |
| VICOP-B | 8.7 |
| EPOCH45 | 8 |
| IFN 3-18 mU48 | 5.4 |
| IFN high dose 16 | 8 |
| Fludarabine 17 | 3 |
| 2-CDA 18,19 | 4, 3 |
| Pentostatin 2-5 mg/m2 x 3 20– 22 | 1.3-8.3 |
| ONTAK 9-18 μg/kg x 5 days 23 | 7.3 |
| Pentostatin and Interferon 24 | 13.1 |
| Fludarabine and Interferon 25 | 6.5 |
| Bexarotene 300mg/m2 daily 26 | 7.5 |
| Treatment . | Response Duration, months (median) . |
|---|---|
| Abbreviations: TSEB, total skin electron beam; CAPO, cyclophosphamide, adriamycin, etoposide, vincristine, prednisone; VICOP-B, idarubicin, etoposide, cyclophosphamide, vincristine, bleomycin, prednisone; EPOCH, etoposide, vincristine, doxorubicin, bolus cyclophosphamide, oral prednisone; IFN, interferon; ONTAK, denileukin diftitox | |
| Pegylated liposomal doxorubicin (PEG-DOXO)10 | 15 |
| TSEB + CAPO31 | 13.7 |
| VICOP-B | 8.7 |
| EPOCH45 | 8 |
| IFN 3-18 mU48 | 5.4 |
| IFN high dose 16 | 8 |
| Fludarabine 17 | 3 |
| 2-CDA 18,19 | 4, 3 |
| Pentostatin 2-5 mg/m2 x 3 20– 22 | 1.3-8.3 |
| ONTAK 9-18 μg/kg x 5 days 23 | 7.3 |
| Pentostatin and Interferon 24 | 13.1 |
| Fludarabine and Interferon 25 | 6.5 |
| Bexarotene 300mg/m2 daily 26 | 7.5 |